董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Matthew Holt director 46 未披露 未持股 2023-08-11
Jeremy Delinsky director 48 未披露 未持股 2023-08-11
John B. Henneman III director 61 19.00万美元 未持股 2023-08-11
Anthony J. Speranzo director and Chairman of the Board 75 19.00万美元 未持股 2023-08-11
Agnes Bundy Scanlan director 65 未披露 未持股 2023-08-11
Bradford Kyle Armbrester director 38 未披露 未持股 2023-08-11
David M. Dill director 55 未披露 未持股 2023-08-11
Lee Rivas director and Chief Executive Officer 49 未披露 未持股 2023-08-11
Janie Wade director 52 未披露 未持股 2023-08-11
Dominic Nakis director -- 未披露 未持股 2023-08-11
Neal Moszkowski director 57 未披露 未持股 2023-08-11
Michael C. Feiner director 82 21.50万美元 未持股 2023-08-11
Jill Smith director 64 21.50万美元 未持股 2023-08-11
Anthony R. Tersigni director 73 19.00万美元 未持股 2023-08-11
Joseph Flanagan director 52 479.46万美元 未持股 2023-08-11
Ian Sacks director 52 未披露 未持股 2023-08-11

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
John Sparby President 47 未披露 未持股 2023-08-11
Lee Rivas director and Chief Executive Officer 49 未披露 未持股 2023-08-11
Kyle Hicok Executive Vice President, Chief Commercial Officer 43 未披露 未持股 2023-08-11
Jennifer Williams Executive Vice President, Chief Financial Officer and Treasurer 46 未披露 未持股 2023-08-11

董事简历

中英对照 |  中文 |  英文
Matthew Holt

Matthew Holt 担任New Mountain Capital LLC的常务董事兼私募股权总裁。自2001年8月以来,他一直专注于医疗产品、健康技术、材料和基础设施等一系列行业的增长收购。霍尔特先生目前在Avantor,Inc.董事会任职,同时也是薪酬委员会成员。Holt 先生担任Datavant、Emids、Finvi、Real Chemistry和Topix Pharmaceuticals的首席董事或董事长。Holt 先生自2017年12月起担任Signify Health,Inc.的董事长。他曾担任Bellerophon Therapeutics,Inc.、Cloudmed、Transfer Health Solutions,Inc.、Cytel、Equian LLC、Gelest、Ikaria,Inc.、Nusil Technology LLC的首席董事,以及MailSouth和TRC公司的董事。Holt 先生拥有哈佛大学英美文学和语言学士学位。


Matthew Holt,has served on the Board since June 2022. Mr. Holt is a Managing Director and President, Private Equity of New Mountain Capital LLC. Since August 2001, he has focused on growth buyouts across a range of industries including healthcare products, health technology, materials and infrastructure. Mr. Holt has served on the board of directors of Avantor, Inc. since 2010, and is chair of Avantor's Compensation & Human Resources Committee. He has also served as chair of the board of directors of Signify Health since December 2017 and serves as a director of a number of privately-held companies. Mr. Holt holds an A.B. in English and American Literature and Language from Harvard College. Mr. Holt is a CoyCo Designee.
Matthew Holt 担任New Mountain Capital LLC的常务董事兼私募股权总裁。自2001年8月以来,他一直专注于医疗产品、健康技术、材料和基础设施等一系列行业的增长收购。霍尔特先生目前在Avantor,Inc.董事会任职,同时也是薪酬委员会成员。Holt 先生担任Datavant、Emids、Finvi、Real Chemistry和Topix Pharmaceuticals的首席董事或董事长。Holt 先生自2017年12月起担任Signify Health,Inc.的董事长。他曾担任Bellerophon Therapeutics,Inc.、Cloudmed、Transfer Health Solutions,Inc.、Cytel、Equian LLC、Gelest、Ikaria,Inc.、Nusil Technology LLC的首席董事,以及MailSouth和TRC公司的董事。Holt 先生拥有哈佛大学英美文学和语言学士学位。
Matthew Holt,has served on the Board since June 2022. Mr. Holt is a Managing Director and President, Private Equity of New Mountain Capital LLC. Since August 2001, he has focused on growth buyouts across a range of industries including healthcare products, health technology, materials and infrastructure. Mr. Holt has served on the board of directors of Avantor, Inc. since 2010, and is chair of Avantor's Compensation & Human Resources Committee. He has also served as chair of the board of directors of Signify Health since December 2017 and serves as a director of a number of privately-held companies. Mr. Holt holds an A.B. in English and American Literature and Language from Harvard College. Mr. Holt is a CoyCo Designee.
Jeremy Delinsky

Jeremy Delinsky,2015年1月起,担任本公司的高级副总裁、首席产品官。2010年7月至2014年12月,他担任高级副总裁、首席技术官;2010年2月至7月,担任athenaNet Intelligence的高级副总裁;2009年1月至2010年2月,担任athenaNet Intelligence的副总裁;2008年11月至2009年1月,担任业务创新副总裁;2006年12月至2008年11月,担任发布业务总监;2006年7月至11月,担任付款人绩效管理总监;2004年11月至2006年7月,担任流程创新PPM总监。他现为Health IT Standards Committee的成员、CommonWell Health Alliance的主席。加入本公司之前,他在 Deloitte Consulting工作了一些,作为医疗保健行业业务的一部分,为支付人组织、学术医学中心担任策略与运营顾问。他在Wesleyan University获得学士学位,在The Wharton School of the University of Pennsylvania获得工商管理硕士学位。


Jeremy Delinsky,has served on the Board since June 2022. Mr. Delinsky has been Chief Operating Officer of Devoted Health, a healthcare company delivering care for Medicare-eligible beneficiaries, since May 2017. From July 2015 to May 2017, Mr. Delinsky was Chief Technology Officer of Wayfair, an online furniture and home products retailer, where he was responsible for 24x7 site operations, software development, security, data science & analytics, and product management of the company's supply chain operations. Prior to joining Wayfair, Mr. Delinsky served at athenahealth as Chief Product Officer from January 2015 to June 2015, as Chief Technology Officer from January 2010 to December 2014, and in a variety of other positions since joining athenahealth in November 2004. During his tenure at athenahealth, Mr. Delinsky was appointed to the Health IT Standards Committee by the Secretary of Health and Human Services and was the founding Chairman of the Board of the CommonWell Health Alliance, an industry trade association focused on the interoperability of electronic health record platforms. Mr. Delinsky began his career in the Strategy & Operations practice at Deloitte Consulting. Mr. Delinsky received a B.A. with Honors from Wesleyan University, where he was elected Phi Beta Kappa, and an M.B.A. from the University of Pennsylvania's Wharton School of Business where he was awarded the Henry J. Kaiser Family Foundation Prize for leadership potential in the field of health care. Mr. Delinsky is a CoyCo Designee.
Jeremy Delinsky,2015年1月起,担任本公司的高级副总裁、首席产品官。2010年7月至2014年12月,他担任高级副总裁、首席技术官;2010年2月至7月,担任athenaNet Intelligence的高级副总裁;2009年1月至2010年2月,担任athenaNet Intelligence的副总裁;2008年11月至2009年1月,担任业务创新副总裁;2006年12月至2008年11月,担任发布业务总监;2006年7月至11月,担任付款人绩效管理总监;2004年11月至2006年7月,担任流程创新PPM总监。他现为Health IT Standards Committee的成员、CommonWell Health Alliance的主席。加入本公司之前,他在 Deloitte Consulting工作了一些,作为医疗保健行业业务的一部分,为支付人组织、学术医学中心担任策略与运营顾问。他在Wesleyan University获得学士学位,在The Wharton School of the University of Pennsylvania获得工商管理硕士学位。
Jeremy Delinsky,has served on the Board since June 2022. Mr. Delinsky has been Chief Operating Officer of Devoted Health, a healthcare company delivering care for Medicare-eligible beneficiaries, since May 2017. From July 2015 to May 2017, Mr. Delinsky was Chief Technology Officer of Wayfair, an online furniture and home products retailer, where he was responsible for 24x7 site operations, software development, security, data science & analytics, and product management of the company's supply chain operations. Prior to joining Wayfair, Mr. Delinsky served at athenahealth as Chief Product Officer from January 2015 to June 2015, as Chief Technology Officer from January 2010 to December 2014, and in a variety of other positions since joining athenahealth in November 2004. During his tenure at athenahealth, Mr. Delinsky was appointed to the Health IT Standards Committee by the Secretary of Health and Human Services and was the founding Chairman of the Board of the CommonWell Health Alliance, an industry trade association focused on the interoperability of electronic health record platforms. Mr. Delinsky began his career in the Strategy & Operations practice at Deloitte Consulting. Mr. Delinsky received a B.A. with Honors from Wesleyan University, where he was elected Phi Beta Kappa, and an M.B.A. from the University of Pennsylvania's Wharton School of Business where he was awarded the Henry J. Kaiser Family Foundation Prize for leadership potential in the field of health care. Mr. Delinsky is a CoyCo Designee.
John B. Henneman III

JohnB.Henneman III,Henneman先生自2016年2月起一直担任我们的董事会成员。Henneman先生自2014年10月起担任生物技术公司Newlink Genetics Corporation的执行Vice President兼首席财务官,负责财务、质量、法律和行政管理。Henneman从1998年到2014年担任Integra LifeSciences Holdings Corp.(一家上市医疗设备公司)多个职位。在2007年成为Integra&;8217;S首席财务官之前,Henneman先生是首席行政官,负责Integra&;S的监管事务、质量体系、临床事务、人力资源、信息系统和法律事务职能,管理Integra&;8217;S的手术器械业务,以及Integra&;8217;S的业务发展职能。Henneman先生是SeaSpine控股公司(一家上市医疗技术公司)和Alafair Biosciences,Inc.(一家私营医疗设备公司)的董事,也是私募股权公司Prettybrook Partners的高级顾问。Henneman先生是一名投资者指定人。


John B. Henneman III,Executive Vice President and Chief Financial Officer of NewLink Genetics Corporation, a public biotechnology company, from October 2014 to July 2018 and Chief Administrative Officer of NewLink from July 2018 through his retirement in November 2018;Various offices of Integra LifeSciences Holdings Corp., a medical devices company, from 1998 to 2014, including Chief Financial Officer from 2007 to 2014 and earlier as General Counsel and Chief Administrative Officer.Aprea Therapeutics Inc. (NASDAQ: APRE), a biotechnology company focused on novel cancer therapeutics, from August 2019 – present (lead independent director from September 2020 - present);R1 RCM, Inc. (NASDAQ: RCM), a provider of revenue cycle management services to healthcare providers, from February 2016 – present (lead independent director from February 2022 - present);SeaSpine Holdings Corporation (NASDAQ: SPNE), a spinal implant and orthobiologics company, from July 2015 through completion of the merger and acquisition by Orthofix Medical Inc. in January 2023;Orthofix Medical, Inc. (NASDAQ: OFIX), a leading global spine and orthopedics company, from January 2023 – present.J.D. from University of Michigan Law School;A.B. in Politics from Princeton University.
JohnB.Henneman III,Henneman先生自2016年2月起一直担任我们的董事会成员。Henneman先生自2014年10月起担任生物技术公司Newlink Genetics Corporation的执行Vice President兼首席财务官,负责财务、质量、法律和行政管理。Henneman从1998年到2014年担任Integra LifeSciences Holdings Corp.(一家上市医疗设备公司)多个职位。在2007年成为Integra&;8217;S首席财务官之前,Henneman先生是首席行政官,负责Integra&;S的监管事务、质量体系、临床事务、人力资源、信息系统和法律事务职能,管理Integra&;8217;S的手术器械业务,以及Integra&;8217;S的业务发展职能。Henneman先生是SeaSpine控股公司(一家上市医疗技术公司)和Alafair Biosciences,Inc.(一家私营医疗设备公司)的董事,也是私募股权公司Prettybrook Partners的高级顾问。Henneman先生是一名投资者指定人。
John B. Henneman III,Executive Vice President and Chief Financial Officer of NewLink Genetics Corporation, a public biotechnology company, from October 2014 to July 2018 and Chief Administrative Officer of NewLink from July 2018 through his retirement in November 2018;Various offices of Integra LifeSciences Holdings Corp., a medical devices company, from 1998 to 2014, including Chief Financial Officer from 2007 to 2014 and earlier as General Counsel and Chief Administrative Officer.Aprea Therapeutics Inc. (NASDAQ: APRE), a biotechnology company focused on novel cancer therapeutics, from August 2019 – present (lead independent director from September 2020 - present);R1 RCM, Inc. (NASDAQ: RCM), a provider of revenue cycle management services to healthcare providers, from February 2016 – present (lead independent director from February 2022 - present);SeaSpine Holdings Corporation (NASDAQ: SPNE), a spinal implant and orthobiologics company, from July 2015 through completion of the merger and acquisition by Orthofix Medical Inc. in January 2023;Orthofix Medical, Inc. (NASDAQ: OFIX), a leading global spine and orthopedics company, from January 2023 – present.J.D. from University of Michigan Law School;A.B. in Politics from Princeton University.
Anthony J. Speranzo

AnthonyJ.Speranzo,Speranzo先生自2016年2月起一直担任我们的董事会成员。Speranzo先生自Ascension Health的母公司Ascension于2011年9月成立以来一直担任该公司的执行Vice President和首席财务官。2002年至2011年9月,Speranzo先生担任Ascension Health的高级副总裁和首席财务官。在加入Ascension Health之前,Speranzo先生曾担任加利福尼亚州纽波特比奇的美国合众银行公司Piper Jaffray USBPJ的常务董事。Speranzo先生还曾在多家医院和企业董事会任职。Speranzo先生是一名投资者指定人。


Anthony J. Speranzo,has served on the Board since February 2016. Mr. Speranzo has been Chief Executive Officer and President of Ascension Capital, LLC, which manages Ascension's investment funds since July 2019. Prior to this role, Mr. Speranzo was Executive Vice President and Chief Financial Officer of Ascension, the parent corporation of Ascension Health, from the corporation's formation in September 2011 until July 2019. From 2002 to September 2011, Mr. Speranzo was Senior Vice President and Chief Financial Officer of Ascension Health. Prior to joining Ascension Health, Mr. Speranzo was Managing Director at U.S. Bancorp Piper Jaffray in Newport Beach, California. Mr. Speranzo has also served on several hospital and corporate boards. Mr. Speranzo is a TCP-ASC Designee.
AnthonyJ.Speranzo,Speranzo先生自2016年2月起一直担任我们的董事会成员。Speranzo先生自Ascension Health的母公司Ascension于2011年9月成立以来一直担任该公司的执行Vice President和首席财务官。2002年至2011年9月,Speranzo先生担任Ascension Health的高级副总裁和首席财务官。在加入Ascension Health之前,Speranzo先生曾担任加利福尼亚州纽波特比奇的美国合众银行公司Piper Jaffray USBPJ的常务董事。Speranzo先生还曾在多家医院和企业董事会任职。Speranzo先生是一名投资者指定人。
Anthony J. Speranzo,has served on the Board since February 2016. Mr. Speranzo has been Chief Executive Officer and President of Ascension Capital, LLC, which manages Ascension's investment funds since July 2019. Prior to this role, Mr. Speranzo was Executive Vice President and Chief Financial Officer of Ascension, the parent corporation of Ascension Health, from the corporation's formation in September 2011 until July 2019. From 2002 to September 2011, Mr. Speranzo was Senior Vice President and Chief Financial Officer of Ascension Health. Prior to joining Ascension Health, Mr. Speranzo was Managing Director at U.S. Bancorp Piper Jaffray in Newport Beach, California. Mr. Speranzo has also served on several hospital and corporate boards. Mr. Speranzo is a TCP-ASC Designee.
Agnes Bundy Scanlan

Agnes Bundy Scanlan,自2020年5月起担任监管咨询公司剑桥集团有限责任公司总裁。2017年至2020年,她担任Trreliant Risk Advisors的高级顾问,就风险管理、战略和其他监管事项为金融服务公司提供咨询服务。2015年至2017年,她担任消费金融保护局东北地区监管考试主任。此前,她曾担任多家银行和金融服务公司的首席监管官、首席合规官、首席隐私官、监管关系执行官、企业社区发展总监,并担任法律顾问,并担任美国参议院预算委员会的法律顾问。Bundy Scanlan女士担任AppFolio,Inc.的董事会成员,AppFolio,Inc.是一家为房地产行业提供基于云的商业软件解决方案、服务和数据分析的供应商,Institutional Capital Network,Inc.是一家私营的全球金融科技平台,为财富管理行业提供另类投资。


Agnes Bundy Scanlan,has served as President of The Cambridge Group LLC, a regulatory advisory firm, since May 2020. From 2017 to 2020, she was a senior advisor for Treliant Risk Advisors, counseling financial services firms on risk management, strategic, and other regulatory matters. From 2015 to 2017, she served as the Northeast Regional Director of Supervision Examinations for the Consumer Financial Protection Bureau. Previously, she served as Chief Regulatory Officer, Chief Compliance Officer, Chief Privacy Officer, Regulatory Relations Executive, and Director of Corporate Community Development for, and as legal counsel to, a number of banks and financial services firms, and as legal counsel to the United States Senate Budget Committee. Ms. Bundy Scanlan serves on the boards of directors of AppFolio, Inc., a provider of cloud-based business software solutions, services, and data analytics to the real estate industry, and Institutional Capital Network, Inc., a privately held global fintech platform driving access to alternative investments for the wealth management industry.
Agnes Bundy Scanlan,自2020年5月起担任监管咨询公司剑桥集团有限责任公司总裁。2017年至2020年,她担任Trreliant Risk Advisors的高级顾问,就风险管理、战略和其他监管事项为金融服务公司提供咨询服务。2015年至2017年,她担任消费金融保护局东北地区监管考试主任。此前,她曾担任多家银行和金融服务公司的首席监管官、首席合规官、首席隐私官、监管关系执行官、企业社区发展总监,并担任法律顾问,并担任美国参议院预算委员会的法律顾问。Bundy Scanlan女士担任AppFolio,Inc.的董事会成员,AppFolio,Inc.是一家为房地产行业提供基于云的商业软件解决方案、服务和数据分析的供应商,Institutional Capital Network,Inc.是一家私营的全球金融科技平台,为财富管理行业提供另类投资。
Agnes Bundy Scanlan,has served as President of The Cambridge Group LLC, a regulatory advisory firm, since May 2020. From 2017 to 2020, she was a senior advisor for Treliant Risk Advisors, counseling financial services firms on risk management, strategic, and other regulatory matters. From 2015 to 2017, she served as the Northeast Regional Director of Supervision Examinations for the Consumer Financial Protection Bureau. Previously, she served as Chief Regulatory Officer, Chief Compliance Officer, Chief Privacy Officer, Regulatory Relations Executive, and Director of Corporate Community Development for, and as legal counsel to, a number of banks and financial services firms, and as legal counsel to the United States Senate Budget Committee. Ms. Bundy Scanlan serves on the boards of directors of AppFolio, Inc., a provider of cloud-based business software solutions, services, and data analytics to the real estate industry, and Institutional Capital Network, Inc., a privately held global fintech platform driving access to alternative investments for the wealth management industry.
Bradford Kyle Armbrester

Bradford Kyle Armbrester(Kyle Armbrester)自2018年4月起担任Signify Health公司的首席执行官和董事。在此之前,Armbrester先生曾在Athenahealth任职,于2015年5月至2018年4月担任高级副总裁兼首席产品官,领导核心产品和运营部门,以及副总裁,2011年5月至2015年5月的战略与企业发展通过战略合作伙伴关系和投资推动企业发展。自2021年9月以来,他一直担任Medalogix的董事。Armbrester先生拥有哈佛商学院的MBA学位和哈佛大学的政府学士学位。


Bradford Kyle Armbrester,has served on the Board since June 2022. Mr. Armbrester has been Chief Executive Officer and a director of Signify Health, a healthcare payments technology company, since April 2018. Prior to this, Mr. Armbrester was Senior Vice President and Chief Product Officer at athenahealth, Inc., a provider of physician billing, practice management and electronic medical records services, from May 2015 to April 2018, leading the core product and operations division, and Vice President, Strategy & Corporate Development from May 2011 to May 2015, driving corporate development through strategic partnerships and investments. He has been a director at Medalogix since September 2021. Mr. Armbrester holds an M.B.A. from Harvard Business School and an A.B. in Government from Harvard University. Mr. Armbrester is a CoyCo Designee.
Bradford Kyle Armbrester(Kyle Armbrester)自2018年4月起担任Signify Health公司的首席执行官和董事。在此之前,Armbrester先生曾在Athenahealth任职,于2015年5月至2018年4月担任高级副总裁兼首席产品官,领导核心产品和运营部门,以及副总裁,2011年5月至2015年5月的战略与企业发展通过战略合作伙伴关系和投资推动企业发展。自2021年9月以来,他一直担任Medalogix的董事。Armbrester先生拥有哈佛商学院的MBA学位和哈佛大学的政府学士学位。
Bradford Kyle Armbrester,has served on the Board since June 2022. Mr. Armbrester has been Chief Executive Officer and a director of Signify Health, a healthcare payments technology company, since April 2018. Prior to this, Mr. Armbrester was Senior Vice President and Chief Product Officer at athenahealth, Inc., a provider of physician billing, practice management and electronic medical records services, from May 2015 to April 2018, leading the core product and operations division, and Vice President, Strategy & Corporate Development from May 2011 to May 2015, driving corporate development through strategic partnerships and investments. He has been a director at Medalogix since September 2021. Mr. Armbrester holds an M.B.A. from Harvard Business School and an A.B. in Government from Harvard University. Mr. Armbrester is a CoyCo Designee.
David M. Dill

David M. Dill,自2021年4月起担任董事会成员。迪尔先生自2021年10月起担任LifePoint Health的董事长兼首席执行官,该公司是一个多元化的医疗保健提供网络。迪尔先生于2007年加入LifePoint,担任执行副总裁兼首席财务官,之后于2009年至2018年担任总裁兼首席运营官,最近于2018年至2021年10月担任总裁兼首席执行官。在加入LifePoint之前,他是费森尤斯医疗北美执行副总裁兼费森尤斯医疗服务东区首席执行官,该公司是费森尤斯医疗股份公司的全资子公司,为肾衰竭和慢性肾病患者提供肾透析及其他产品和解决方案。迪尔先生曾任美国医院联合会理事会主席,目前担任联合会理事会和执行委员会成员。他还是纳什维尔保健委员会董事会主席和默里州立大学基金会董事会成员。


David M. Dill,has served on the Board since April 2021. Mr. Dill has been the Chairman and Chief Executive Officer of LifePoint Health, a diversified healthcare delivery network, since October 2021. Mr. Dill joined LifePoint in 2007 as Executive Vice President and Chief Financial Officer before serving as President and Chief Operating Officer from 2009 to 2018 and in his most recent role as President and Chief Executive Officer from 2018 to October 2021. Before joining LifePoint, he was Executive Vice President of Fresenius Medical Care North America and Chief Executive Officer in the East Division of Fresenius Medical Care Services, a wholly owned subsidiary of Fresenius Medical Care AG & Co. KGaA, a provider of kidney dialysis and other products and solutions for patients with renal failure and chronic kidney disease. Mr. Dill is a former chairman of the board for the Federation of American Hospitals and currently serves as a member of the Federation's board and Executive Committee. He is also chair of the board of directors for the Nashville Health Care Council and a member of the board of trustees for the Murray State University Foundation.
David M. Dill,自2021年4月起担任董事会成员。迪尔先生自2021年10月起担任LifePoint Health的董事长兼首席执行官,该公司是一个多元化的医疗保健提供网络。迪尔先生于2007年加入LifePoint,担任执行副总裁兼首席财务官,之后于2009年至2018年担任总裁兼首席运营官,最近于2018年至2021年10月担任总裁兼首席执行官。在加入LifePoint之前,他是费森尤斯医疗北美执行副总裁兼费森尤斯医疗服务东区首席执行官,该公司是费森尤斯医疗股份公司的全资子公司,为肾衰竭和慢性肾病患者提供肾透析及其他产品和解决方案。迪尔先生曾任美国医院联合会理事会主席,目前担任联合会理事会和执行委员会成员。他还是纳什维尔保健委员会董事会主席和默里州立大学基金会董事会成员。
David M. Dill,has served on the Board since April 2021. Mr. Dill has been the Chairman and Chief Executive Officer of LifePoint Health, a diversified healthcare delivery network, since October 2021. Mr. Dill joined LifePoint in 2007 as Executive Vice President and Chief Financial Officer before serving as President and Chief Operating Officer from 2009 to 2018 and in his most recent role as President and Chief Executive Officer from 2018 to October 2021. Before joining LifePoint, he was Executive Vice President of Fresenius Medical Care North America and Chief Executive Officer in the East Division of Fresenius Medical Care Services, a wholly owned subsidiary of Fresenius Medical Care AG & Co. KGaA, a provider of kidney dialysis and other products and solutions for patients with renal failure and chronic kidney disease. Mr. Dill is a former chairman of the board for the Federation of American Hospitals and currently serves as a member of the Federation's board and Executive Committee. He is also chair of the board of directors for the Nashville Health Care Council and a member of the board of trustees for the Murray State University Foundation.
Lee Rivas

Lee Rivas,自2023年1月起担任R1董事会成员和首席执行官。他曾在2022年6月R1完成对Revint Holdings,LLC(“Cloudmed”)的收购后担任R1总裁,直到2022年12月,在此期间,他领导了Cloudmed成功的交易后整合,在商业卓越、行业专业知识、可扩展技术和智能自动化的基础上建立了一个全面的收入周期平台。里瓦斯先生在技术和医疗保健领域拥有20多年的领导经验。在加入R1之前,他于2020年6月至2022年6月担任Cloudmed首席执行官。从2006年6月至2020年5月,Rivas先生还是全球信息分析解决方案提供商RELX的高级主管。他在RELX的最后一个职位是医疗保健部门的总经理兼总裁,负责Elsevier和LexisNexis风险解决方案部门超过10亿美元的收入。在加入RELX之前,里瓦斯先生是麦肯锡公司的项目经理。他的职业生涯始于美国陆军军官,在美国和国外担任过多个领导职务。里瓦斯毕业于美国西点军校,并拥有哈佛商学院的工商管理硕士学位。


Lee Rivas,has served on the Board and as Chief Executive Officer of R1 since January 2023. He was previously President of R1 from June 2022, when R1 closed the acquisition of Revint Holdings, LLC ("Cloudmed"), until December 2022, during which time he led a successful post-transaction integration of Cloudmed, building a comprehensive revenue cycle platform on a foundation of commercial excellence, industry expertise, scalable technology, and intelligent automation. Mr. Rivas has more than 20 years of leadership experience in technology and healthcare. Prior to joining R1, he was Chief Executive Officer of Cloudmed from June 2020 to June 2022. From June 2006 to May 2020, Mr. Rivas was also a senior leader at RELX, a global provider of information analytics solutions. His last role at RELX was General Manager and President of the healthcare segment, with responsibility over $1 billion in revenue across the Elsevier and LexisNexis Risk Solutions division. Prior to RELX, Mr. Rivas was an engagement manager with McKinsey & Company. He began his career as an officer in the U.S. Army, where he held several leadership positions in the U.S. and abroad. Mr. Rivas is a graduate of the United States Military Academy at West Point and has an M.B.A. from Harvard Business School.
Lee Rivas,自2023年1月起担任R1董事会成员和首席执行官。他曾在2022年6月R1完成对Revint Holdings,LLC(“Cloudmed”)的收购后担任R1总裁,直到2022年12月,在此期间,他领导了Cloudmed成功的交易后整合,在商业卓越、行业专业知识、可扩展技术和智能自动化的基础上建立了一个全面的收入周期平台。里瓦斯先生在技术和医疗保健领域拥有20多年的领导经验。在加入R1之前,他于2020年6月至2022年6月担任Cloudmed首席执行官。从2006年6月至2020年5月,Rivas先生还是全球信息分析解决方案提供商RELX的高级主管。他在RELX的最后一个职位是医疗保健部门的总经理兼总裁,负责Elsevier和LexisNexis风险解决方案部门超过10亿美元的收入。在加入RELX之前,里瓦斯先生是麦肯锡公司的项目经理。他的职业生涯始于美国陆军军官,在美国和国外担任过多个领导职务。里瓦斯毕业于美国西点军校,并拥有哈佛商学院的工商管理硕士学位。
Lee Rivas,has served on the Board and as Chief Executive Officer of R1 since January 2023. He was previously President of R1 from June 2022, when R1 closed the acquisition of Revint Holdings, LLC ("Cloudmed"), until December 2022, during which time he led a successful post-transaction integration of Cloudmed, building a comprehensive revenue cycle platform on a foundation of commercial excellence, industry expertise, scalable technology, and intelligent automation. Mr. Rivas has more than 20 years of leadership experience in technology and healthcare. Prior to joining R1, he was Chief Executive Officer of Cloudmed from June 2020 to June 2022. From June 2006 to May 2020, Mr. Rivas was also a senior leader at RELX, a global provider of information analytics solutions. His last role at RELX was General Manager and President of the healthcare segment, with responsibility over $1 billion in revenue across the Elsevier and LexisNexis Risk Solutions division. Prior to RELX, Mr. Rivas was an engagement manager with McKinsey & Company. He began his career as an officer in the U.S. Army, where he held several leadership positions in the U.S. and abroad. Mr. Rivas is a graduate of the United States Military Academy at West Point and has an M.B.A. from Harvard Business School.
Janie Wade

珍妮韦德,自2023年1月起担任董事会成员。Wade女士自2023年1月起担任Intermountain Healthcare的首席财务官。Intermountain Healthcare是一家位于犹他州的非营利性医疗保健系统。她曾在2022年4月至2023年期间担任Intermountain的企业运营首席财务官,并在Intermountain与SCL Health合并后领导财务整合,负责运营财务、会计、内部审计、收入周期、付款人合同、财务以及财务规划和分析方面的领导和监督。此前,Wade女士于2018年2月至2022年3月担任SCL Health的执行副总裁兼首席财务官。在加入SCL Health之前,Wade女士曾担任Baylor Scott和White Health的财务高级副总裁,以及Arthur Andersen,LLP达拉斯办事处的经理。作为一名注册会计师,韦德拥有德克萨斯州商业大学的工商管理硕士学位,以及德克萨斯州大学城的德州农工大学的工商管理学士学位。韦德女士自2020年起担任科罗拉多医疗保健负担能力和可持续性企业的董事会成员,同时也是医疗保健财务管理协会的成员。Wade女士是Intermountain Designee。


Janie Wade,has served on the Board since January 2023. Ms. Wade has served as Chief Financial Officer of Intermountain Healthcare, a not-for-profit healthcare system based in Utah, since January 2023. She previously served as Intermountain's Chief Financial Officer, Enterprise Operations from April 2022 until 2023 and led the financial integration following Intermountain's merger with SCL Health, providing leadership and oversight for operational finance, accounting, internal audit, revenue cycle, payer contracting, treasury, and financial planning and analysis. Previously, Ms. Wade served as Executive Vice President and Chief Financial Officer of SCL Health from February 2018 to March 2022. Before joining SCL Health, Ms. Wade served as Senior Vice President of Finance for Baylor Scott and White Health and as a Manager at Arthur Andersen, LLP in the Dallas office. A Certified Public Accountant, Ms. Wade holds an M.B.A. from Texas A&M University in Commerce, Texas and a Bachelor's of Business Administration from Texas A&M University in College Station, Texas. Ms. Wade has served as a board member of the Colorado Healthcare Affordability and Sustainability Enterprise since 2020, and is also a member of the Healthcare Financial Management Association. Ms. Wade is the Intermountain Designee.
珍妮韦德,自2023年1月起担任董事会成员。Wade女士自2023年1月起担任Intermountain Healthcare的首席财务官。Intermountain Healthcare是一家位于犹他州的非营利性医疗保健系统。她曾在2022年4月至2023年期间担任Intermountain的企业运营首席财务官,并在Intermountain与SCL Health合并后领导财务整合,负责运营财务、会计、内部审计、收入周期、付款人合同、财务以及财务规划和分析方面的领导和监督。此前,Wade女士于2018年2月至2022年3月担任SCL Health的执行副总裁兼首席财务官。在加入SCL Health之前,Wade女士曾担任Baylor Scott和White Health的财务高级副总裁,以及Arthur Andersen,LLP达拉斯办事处的经理。作为一名注册会计师,韦德拥有德克萨斯州商业大学的工商管理硕士学位,以及德克萨斯州大学城的德州农工大学的工商管理学士学位。韦德女士自2020年起担任科罗拉多医疗保健负担能力和可持续性企业的董事会成员,同时也是医疗保健财务管理协会的成员。Wade女士是Intermountain Designee。
Janie Wade,has served on the Board since January 2023. Ms. Wade has served as Chief Financial Officer of Intermountain Healthcare, a not-for-profit healthcare system based in Utah, since January 2023. She previously served as Intermountain's Chief Financial Officer, Enterprise Operations from April 2022 until 2023 and led the financial integration following Intermountain's merger with SCL Health, providing leadership and oversight for operational finance, accounting, internal audit, revenue cycle, payer contracting, treasury, and financial planning and analysis. Previously, Ms. Wade served as Executive Vice President and Chief Financial Officer of SCL Health from February 2018 to March 2022. Before joining SCL Health, Ms. Wade served as Senior Vice President of Finance for Baylor Scott and White Health and as a Manager at Arthur Andersen, LLP in the Dallas office. A Certified Public Accountant, Ms. Wade holds an M.B.A. from Texas A&M University in Commerce, Texas and a Bachelor's of Business Administration from Texas A&M University in College Station, Texas. Ms. Wade has served as a board member of the Colorado Healthcare Affordability and Sustainability Enterprise since 2020, and is also a member of the Healthcare Financial Management Association. Ms. Wade is the Intermountain Designee.
Dominic Nakis

Dominic Nakis,现任Sutter高级副总裁兼临时首席财务官,负责Sutter的整体财务运营,包括财务规划和分析、投资、财务、会计和控制、收入周期、决策支持、管理式医疗承包、精算和核保。纳基斯还负责供应链和萨特的健康计划。在2023年4月加入Sutter之前,Nakis先生在Advocate Aurora Health(“Advocate”)及其前身组织担任各种职务超过35年,最近于2018年4月至2023年3月担任首席财务官和Advocate董事会财务主管。纳基斯的职业生涯始于安永在芝加哥的保险业务。他是医疗保健财务管理协会和美国医院协会投资委员会的成员,也是医疗保健财务管理协会国家原则和实践委员会的前成员。纳基斯在伊利诺伊大学芝加哥分校获得会计学学士学位,在德保罗大学凯尔施塔特商学院获得MBA学位。Nakis先生是一名注册会计师。


Dominic Nakis,currently serves as Sutter's Senior Vice President and Interim Chief Financial Officer, where he is responsible for Sutter's overall financial operations, including financial planning and analysis, investments, treasury, accounting and controls, revenue cycle, decision support, managed care contracting, actuarial, and underwriting. Mr. Nakis also oversees supply chain and Sutter's health plan. Prior to joining Sutter in April 2023, Mr. Nakis held various roles at Advocate Aurora Health ("Advocate") and its predecessor organizations for over 35 years, most recently serving as Chief Financial Officer and Advocate Board Treasurer from April 2018 to March 2023. Mr. Nakis began his career in the assurance practice at Ernst & Young in Chicago. He is a member of the Healthcare Financial Management Association and the American Hospital Association Investment Committee, and is a past member of the Healthcare Financial Management Association's National Principles and Practices Board. Mr. Nakis earned a bachelor's degree in accounting from the University of Illinois at Chicago and an MBA from DePaul University's Kellstadt Graduate School of Business. Mr. Nakis is a certified public accountant.
Dominic Nakis,现任Sutter高级副总裁兼临时首席财务官,负责Sutter的整体财务运营,包括财务规划和分析、投资、财务、会计和控制、收入周期、决策支持、管理式医疗承包、精算和核保。纳基斯还负责供应链和萨特的健康计划。在2023年4月加入Sutter之前,Nakis先生在Advocate Aurora Health(“Advocate”)及其前身组织担任各种职务超过35年,最近于2018年4月至2023年3月担任首席财务官和Advocate董事会财务主管。纳基斯的职业生涯始于安永在芝加哥的保险业务。他是医疗保健财务管理协会和美国医院协会投资委员会的成员,也是医疗保健财务管理协会国家原则和实践委员会的前成员。纳基斯在伊利诺伊大学芝加哥分校获得会计学学士学位,在德保罗大学凯尔施塔特商学院获得MBA学位。Nakis先生是一名注册会计师。
Dominic Nakis,currently serves as Sutter's Senior Vice President and Interim Chief Financial Officer, where he is responsible for Sutter's overall financial operations, including financial planning and analysis, investments, treasury, accounting and controls, revenue cycle, decision support, managed care contracting, actuarial, and underwriting. Mr. Nakis also oversees supply chain and Sutter's health plan. Prior to joining Sutter in April 2023, Mr. Nakis held various roles at Advocate Aurora Health ("Advocate") and its predecessor organizations for over 35 years, most recently serving as Chief Financial Officer and Advocate Board Treasurer from April 2018 to March 2023. Mr. Nakis began his career in the assurance practice at Ernst & Young in Chicago. He is a member of the Healthcare Financial Management Association and the American Hospital Association Investment Committee, and is a past member of the Healthcare Financial Management Association's National Principles and Practices Board. Mr. Nakis earned a bachelor's degree in accounting from the University of Illinois at Chicago and an MBA from DePaul University's Kellstadt Graduate School of Business. Mr. Nakis is a certified public accountant.
Neal Moszkowski

Neal Moszkowski,自2016年2月起担任董事会成员。他是TowerBrook Capital Partners l.p.(一家投资管理公司)的联合创始人兼联合主席,并担任该公司的联合首席执行官(从2005年3月成立到2022年2月)。Moszkowski先生是Compassus (TowerBrook投资组合公司)的董事。他曾担任WellCare Health Plans和Sound Inpatient Holdings(前TowerBrook投资组合公司)的董事会成员,以及Integra LifeSciences Holdings Corporation和JetBlue的董事会成员。Moszkowski先生是TCP-ASC指定人员。


Neal Moszkowski,has served on the Board since February 2016. Mr. Moszkowski is a co-founder and co-chair of TowerBrook Capital Partners L.P., an investment management firm, and served as the firm's co-chief executive officer from its inception in March 2005 until February 2022. Mr. Moszkowski is a director of Compassus, a TowerBrook portfolio company. Mr. Moszkowski's past directorships include service on the boards of WellCare Health Plans and Sound Inpatient Holdings, former TowerBrook portfolio companies, as well as the board of Integra LifeSciences Holdings Corporation and JetBlue. Mr. Moszkowski is a TCP-ASC Designee.
Neal Moszkowski,自2016年2月起担任董事会成员。他是TowerBrook Capital Partners l.p.(一家投资管理公司)的联合创始人兼联合主席,并担任该公司的联合首席执行官(从2005年3月成立到2022年2月)。Moszkowski先生是Compassus (TowerBrook投资组合公司)的董事。他曾担任WellCare Health Plans和Sound Inpatient Holdings(前TowerBrook投资组合公司)的董事会成员,以及Integra LifeSciences Holdings Corporation和JetBlue的董事会成员。Moszkowski先生是TCP-ASC指定人员。
Neal Moszkowski,has served on the Board since February 2016. Mr. Moszkowski is a co-founder and co-chair of TowerBrook Capital Partners L.P., an investment management firm, and served as the firm's co-chief executive officer from its inception in March 2005 until February 2022. Mr. Moszkowski is a director of Compassus, a TowerBrook portfolio company. Mr. Moszkowski's past directorships include service on the boards of WellCare Health Plans and Sound Inpatient Holdings, former TowerBrook portfolio companies, as well as the board of Integra LifeSciences Holdings Corporation and JetBlue. Mr. Moszkowski is a TCP-ASC Designee.
Michael C. Feiner

Michael C. Feiner自2010年12月担任董事。Feiner先生是Michael C. Feiner咨询股份有限公司的创始人,该公司是一家咨询公司,其主要业务集中在向公司提供人力资源资本策略、组织开发和领导层效能的建议。自公司1996年创立他就担任总裁。Feiner先生还担任欧文宫殿资本公司主管人力资源资本的高级常务董事,该公司是一家位于纽约州纽约市的私人实体基金。从2003年到2010年,Feiner先生担任哥伦比亚商学院的教授和Sanford C. Bernstein公司的合伙人。Feiner先生从1975年到1995年担任百事可乐公司的高级副总裁,同时从1989年到他1995年退休担任百事可乐世界饮品运营部首席人员官。他所写的书《Feiner的领导者观点:员工为你更好努力工作的50个基本法则》被多伦多邮报评选为2004年度最佳商业书刊。


Michael C. Feiner,has served on the Board since March 2017. Mr. Feiner is the founder of Michael C. Feiner Consulting, Inc., a consulting firm specializing in advising companies on human capital strategies, organization development and leadership effectiveness. He has been its President since the firm's founding in 1996. Mr. Feiner was also Senior Advisor for Irving Place Capital, a private equity fund located in New York, New York, from 2011 to 2015. From 2000 to 2010, Mr. Feiner was a professor and the Sanford C. Bernstein & Co. Ethics Fellow at Columbia Business School. Mr. Feiner worked for Pepsi-Cola Company from 1975 to 1995 where he was Senior Vice President and Chief People Officer for Pepsi's beverage operations worldwide from 1989 until his retirement in 1995. Mr. Feiner also served on the board of Agiliti, Inc. (f/k/a Universal Hospital Services, Inc.), a medical equipment rental and services company, from to June 2012 until January 2019. His book, The Feiner Points of Leadership: The 50 Basic Laws That Will Make People Want to Perform Better for You, was selected by the Toronto Globe and Mail as the Best Business Book of 2004. Mr. Feiner is a TCP-ASC Designee.
Michael C. Feiner自2010年12月担任董事。Feiner先生是Michael C. Feiner咨询股份有限公司的创始人,该公司是一家咨询公司,其主要业务集中在向公司提供人力资源资本策略、组织开发和领导层效能的建议。自公司1996年创立他就担任总裁。Feiner先生还担任欧文宫殿资本公司主管人力资源资本的高级常务董事,该公司是一家位于纽约州纽约市的私人实体基金。从2003年到2010年,Feiner先生担任哥伦比亚商学院的教授和Sanford C. Bernstein公司的合伙人。Feiner先生从1975年到1995年担任百事可乐公司的高级副总裁,同时从1989年到他1995年退休担任百事可乐世界饮品运营部首席人员官。他所写的书《Feiner的领导者观点:员工为你更好努力工作的50个基本法则》被多伦多邮报评选为2004年度最佳商业书刊。
Michael C. Feiner,has served on the Board since March 2017. Mr. Feiner is the founder of Michael C. Feiner Consulting, Inc., a consulting firm specializing in advising companies on human capital strategies, organization development and leadership effectiveness. He has been its President since the firm's founding in 1996. Mr. Feiner was also Senior Advisor for Irving Place Capital, a private equity fund located in New York, New York, from 2011 to 2015. From 2000 to 2010, Mr. Feiner was a professor and the Sanford C. Bernstein & Co. Ethics Fellow at Columbia Business School. Mr. Feiner worked for Pepsi-Cola Company from 1975 to 1995 where he was Senior Vice President and Chief People Officer for Pepsi's beverage operations worldwide from 1989 until his retirement in 1995. Mr. Feiner also served on the board of Agiliti, Inc. (f/k/a Universal Hospital Services, Inc.), a medical equipment rental and services company, from to June 2012 until January 2019. His book, The Feiner Points of Leadership: The 50 Basic Laws That Will Make People Want to Perform Better for You, was selected by the Toronto Globe and Mail as the Best Business Book of 2004. Mr. Feiner is a TCP-ASC Designee.
Jill Smith

Jill Smith 直到目前担任DigitalGlobe股份有限公司(DigitalGlobe, Inc.,给商业和政府客户提供全球卫星信息产品和服务的领先供应商)的董事长和首席执行官。她先前担任eDial(合作软件公司)的总裁和首席执行官,也是SRDS, L.P.(一家私人的出版和印刷公司)的首席执行官,还是 Micron Electronics股份有限公司( Micron Electronics, Inc.,直接个人电脑制造商和市场商)的运营总监。另外,她联合创立并领导Treacy & Company有限责任公司(Treacy & Company, LLC,一家咨询和精品投资业务)。她的早期专业经验包括在Sara Lee 公司(Sara Lee Corporation )担任执行职位,在 Bain & 公司( Bain & Company)担任副总裁。她拥有麻省理工学院斯隆管理学院(MIT Sloan School of Manment)的工商管理硕士学位。


Jill Smith,has served on the Board since April 2019. Most recently, Ms. Smith was President and Chief Executive Officer of Allied Minds plc, a technology commercialization company, from March 2017 to June 2019, and prior to that was Chairman, Chief Executive Officer and President of DigitalGlobe Inc., a global provider of satellite imagery products and services. Ms. Smith started her career as a consultant at Bain & Company, where she most recently served as a Partner. She subsequently joined Sara Lee as Vice President, and went on to serve as President and Chief Executive Officer of eDial, a VoIP collaboration company, and of SRDS, a business-to-business publishing firm. She also served as Chief Operating Officer of Micron Electronics, and co-founded Treacy & Company, a consulting and boutique investment business. Ms. Smith has served as a director of Aspen Technology, Inc. since April 2021, CIRCOR International, Inc. since January 2020, and MDA Ltd. since 2019. She previously served as a director of Gemalto NV from 2016 to 2018, Allied Minds from 2016 to 2019, Endo International from 2012 to 2018 and Hexagon AB from 2013 to 2017.
Jill Smith 直到目前担任DigitalGlobe股份有限公司(DigitalGlobe, Inc.,给商业和政府客户提供全球卫星信息产品和服务的领先供应商)的董事长和首席执行官。她先前担任eDial(合作软件公司)的总裁和首席执行官,也是SRDS, L.P.(一家私人的出版和印刷公司)的首席执行官,还是 Micron Electronics股份有限公司( Micron Electronics, Inc.,直接个人电脑制造商和市场商)的运营总监。另外,她联合创立并领导Treacy & Company有限责任公司(Treacy & Company, LLC,一家咨询和精品投资业务)。她的早期专业经验包括在Sara Lee 公司(Sara Lee Corporation )担任执行职位,在 Bain & 公司( Bain & Company)担任副总裁。她拥有麻省理工学院斯隆管理学院(MIT Sloan School of Manment)的工商管理硕士学位。
Jill Smith,has served on the Board since April 2019. Most recently, Ms. Smith was President and Chief Executive Officer of Allied Minds plc, a technology commercialization company, from March 2017 to June 2019, and prior to that was Chairman, Chief Executive Officer and President of DigitalGlobe Inc., a global provider of satellite imagery products and services. Ms. Smith started her career as a consultant at Bain & Company, where she most recently served as a Partner. She subsequently joined Sara Lee as Vice President, and went on to serve as President and Chief Executive Officer of eDial, a VoIP collaboration company, and of SRDS, a business-to-business publishing firm. She also served as Chief Operating Officer of Micron Electronics, and co-founded Treacy & Company, a consulting and boutique investment business. Ms. Smith has served as a director of Aspen Technology, Inc. since April 2021, CIRCOR International, Inc. since January 2020, and MDA Ltd. since 2019. She previously served as a director of Gemalto NV from 2016 to 2018, Allied Minds from 2016 to 2019, Endo International from 2012 to 2018 and Hexagon AB from 2013 to 2017.
Anthony R. Tersigni

Anthony R. Tersigni从2012年5月开始担任ProAssurance的董事。 Tersigni博士担任密苏里州圣路易斯的阿森松医疗集团(Ascension Health Alliance)的总裁和首席执行官,其为阿森松保健公司(Ascension Health)的控股母公司。阿森松保健是美国最大的非盈利机构和最大的天主教健康系统。设立控股公司组织架构前,Tersigni博士担任阿森松保健的总裁兼首席执行官超过7年时间。Tersigni博士在密西根州卡拉马祖市的西密执安大学(Western Michigan University)获得领导力与组织发展专业的博士学位,并在阿奎那神学研究所(Aquinas Institute of Theology)和圣路易斯大学(St. Louis University)获得荣誉博士学位。


Anthony R. Tersigni,has served on the Board since August 2019. Dr. Tersigni has been Chair of the Board of Ascension Capital, LLC, Ascension's healthcare investment fund since July 2019. Prior to this role, Dr. Tersigni was President and Chief Executive Officer of Ascension from January 2012 until January 2019. Dr. Tersigni also served on the board of ProAssurance Corporation from May 2012 to May 2015. Before becoming the first President and Chief Executive Officer of Ascension in 2012, Dr. Tersigni had served as President and Chief Executive Officer of Ascension Health since 2004. Previously he served as Ascension Health's Executive Vice President and Chief Operating Officer from 2001 through 2003. From 1995 to 2000, Dr. Tersigni was President and Chief Executive Officer at St. John Health, Detroit (now Ascension St. John-Providence Health), which at that time was Ascension Health's largest integrated health system. Dr. Tersigni is a TCP-ASC Designee.
Anthony R. Tersigni从2012年5月开始担任ProAssurance的董事。 Tersigni博士担任密苏里州圣路易斯的阿森松医疗集团(Ascension Health Alliance)的总裁和首席执行官,其为阿森松保健公司(Ascension Health)的控股母公司。阿森松保健是美国最大的非盈利机构和最大的天主教健康系统。设立控股公司组织架构前,Tersigni博士担任阿森松保健的总裁兼首席执行官超过7年时间。Tersigni博士在密西根州卡拉马祖市的西密执安大学(Western Michigan University)获得领导力与组织发展专业的博士学位,并在阿奎那神学研究所(Aquinas Institute of Theology)和圣路易斯大学(St. Louis University)获得荣誉博士学位。
Anthony R. Tersigni,has served on the Board since August 2019. Dr. Tersigni has been Chair of the Board of Ascension Capital, LLC, Ascension's healthcare investment fund since July 2019. Prior to this role, Dr. Tersigni was President and Chief Executive Officer of Ascension from January 2012 until January 2019. Dr. Tersigni also served on the board of ProAssurance Corporation from May 2012 to May 2015. Before becoming the first President and Chief Executive Officer of Ascension in 2012, Dr. Tersigni had served as President and Chief Executive Officer of Ascension Health since 2004. Previously he served as Ascension Health's Executive Vice President and Chief Operating Officer from 2001 through 2003. From 1995 to 2000, Dr. Tersigni was President and Chief Executive Officer at St. John Health, Detroit (now Ascension St. John-Providence Health), which at that time was Ascension Health's largest integrated health system. Dr. Tersigni is a TCP-ASC Designee.
Joseph Flanagan

Joseph Flanagan,他曾担任R1 Rcm Inc.的总裁、首席执行官和董事会成员(2016年5月以来)。在2013年4月加入R1担任首席运营官之前,他曾于2010年至2013年担任Applied Materials, Inc.全球运营和供应链高级副总裁。从2006年到2010年,他还担任Nortel Networks业务服务总裁的领导职务。在Nortel 之前,他的执行轨迹始于在通用电气(General Electric GE)工作,从1993年到2006年在许多部门担任管理职务。目前,他还担任GoHealth的董事会成员。


Joseph Flanagan,has served on the Board since May 2016 and has been Executive Advisor to the Chief Executive Officer of R1 since January 2023. Previously, Mr. Flanagan served as Chief Executive Officer of R1 since June 2021 and as President and Chief Executive Officer of R1 from May 2016 until June 2021. Before joining R1 as Chief Operating Officer in April 2013, he was senior vice president of worldwide operations and supply chain at Applied Materials, Inc. from 2010 to 2013. He also held leadership positions up to President of Nortel Business Services for Nortel Networks from 2006 to 2010. Prior to Nortel, his executive trajectory began while working for General Electric, holding management positions in many divisions from 1993 to 2006. Mr. Flanagan also serves on the board directors of GoHealth.
Joseph Flanagan,他曾担任R1 Rcm Inc.的总裁、首席执行官和董事会成员(2016年5月以来)。在2013年4月加入R1担任首席运营官之前,他曾于2010年至2013年担任Applied Materials, Inc.全球运营和供应链高级副总裁。从2006年到2010年,他还担任Nortel Networks业务服务总裁的领导职务。在Nortel 之前,他的执行轨迹始于在通用电气(General Electric GE)工作,从1993年到2006年在许多部门担任管理职务。目前,他还担任GoHealth的董事会成员。
Joseph Flanagan,has served on the Board since May 2016 and has been Executive Advisor to the Chief Executive Officer of R1 since January 2023. Previously, Mr. Flanagan served as Chief Executive Officer of R1 since June 2021 and as President and Chief Executive Officer of R1 from May 2016 until June 2021. Before joining R1 as Chief Operating Officer in April 2013, he was senior vice president of worldwide operations and supply chain at Applied Materials, Inc. from 2010 to 2013. He also held leadership positions up to President of Nortel Business Services for Nortel Networks from 2006 to 2010. Prior to Nortel, his executive trajectory began while working for General Electric, holding management positions in many divisions from 1993 to 2006. Mr. Flanagan also serves on the board directors of GoHealth.
Ian Sacks

自2004年4月以来,Ian Sacks 曾担任公司董事。自2004年以来,他一直任TowerBrook Capital Partners L.P运营总监,这是一家投资管理公司,他专注于医疗保健及相关业务服务的投资。他曾是Soros Private Equity 管理合伙人,并在加入该公司前,他是HelpCare的董事长兼首席执行官。他还担任若干私人公司董事。他持有Tufts大学学士学位。


Ian Sacks,has served on the Board since February 2016. Mr. Sacks is a Managing Director of TowerBrook, where he focuses on healthcare and business services related investments, and has been at the firm since its inception in 2005. Prior to joining TowerBrook, Mr. Sacks was a Management Partner of Soros Private Equity Partners and Chairman and Chief Executive Officer of HelpCare prior to that. Mr. Sacks has served as a director of HealthEquity, Inc. since April 2004. He also serves on the board of directors of TriMedx, Compassus, and Regent Surgical, each of which is a TowerBrook portfolio company. Previously, Mr. Sacks served as a director of Sound Inpatient Physicians and The Broadlane Group, as well as Vistage Worldwide, all prior TowerBrook portfolio companies. Mr. Sacks is a TCP-ASC Designee.
自2004年4月以来,Ian Sacks 曾担任公司董事。自2004年以来,他一直任TowerBrook Capital Partners L.P运营总监,这是一家投资管理公司,他专注于医疗保健及相关业务服务的投资。他曾是Soros Private Equity 管理合伙人,并在加入该公司前,他是HelpCare的董事长兼首席执行官。他还担任若干私人公司董事。他持有Tufts大学学士学位。
Ian Sacks,has served on the Board since February 2016. Mr. Sacks is a Managing Director of TowerBrook, where he focuses on healthcare and business services related investments, and has been at the firm since its inception in 2005. Prior to joining TowerBrook, Mr. Sacks was a Management Partner of Soros Private Equity Partners and Chairman and Chief Executive Officer of HelpCare prior to that. Mr. Sacks has served as a director of HealthEquity, Inc. since April 2004. He also serves on the board of directors of TriMedx, Compassus, and Regent Surgical, each of which is a TowerBrook portfolio company. Previously, Mr. Sacks served as a director of Sound Inpatient Physicians and The Broadlane Group, as well as Vistage Worldwide, all prior TowerBrook portfolio companies. Mr. Sacks is a TCP-ASC Designee.

高管简历

中英对照 |  中文 |  英文
John Sparby

John Sparby自2021年1月起担任运营与交付副总裁兼首席运营官。他最近担任客户运营执行副总裁,担任公司收入周期客户业务的运营负责人。Sparby先生于2004年1月加入本公司担任客户主管,此后于2008年1月至2010年12月担任本公司共享服务运营主管,2011年1月至2013年12月担任东区总经理,高级副总裁,2014年1月至2016年12月担任客户运营,2017年1月至2020年12月担任客户运营执行副总裁。在加入公司之前,Sparby先生在Stockamp & Associates工作了六年,领导主要针对学术卫生系统的大规模端到端收入周期重新设计项目,实现了显着的损益表和资产负债表改进。


John Sparby,has served as R1 Rcm Inc. President since January 2023. Previously, Mr. Sparby was R1 Rcm Inc. Executive Vice President, Operations & Delivery and Chief Operating Officer from January 2021 to June 2022 and R1 Rcm Inc. Executive Vice President, Chief Solutions and Customer Officer from June 2022 to December 2022. Prior to that role, he served as Executive Vice President, Customer Operations as the operational leader of R1 Rcm Inc. revenue cycle customer engagements from January 2017 to December 2020. Mr. Sparby joined R1 in January 2004 as Customer Executive and has since served R1 as Shared Services Operating Executive from January 2008 to December 2010, General Manager, East Region from January 2011 to December 2013, and Senior Vice President, Customer Operations from January 2014 to December 2016. Prior to joining R1, Mr. Sparby spent six years at Stockamp & Associates leading large-scale, end to end revenue cycle re-engineering projects for primarily academic health systems achieving significant income statement and balance sheet improvements.
John Sparby自2021年1月起担任运营与交付副总裁兼首席运营官。他最近担任客户运营执行副总裁,担任公司收入周期客户业务的运营负责人。Sparby先生于2004年1月加入本公司担任客户主管,此后于2008年1月至2010年12月担任本公司共享服务运营主管,2011年1月至2013年12月担任东区总经理,高级副总裁,2014年1月至2016年12月担任客户运营,2017年1月至2020年12月担任客户运营执行副总裁。在加入公司之前,Sparby先生在Stockamp & Associates工作了六年,领导主要针对学术卫生系统的大规模端到端收入周期重新设计项目,实现了显着的损益表和资产负债表改进。
John Sparby,has served as R1 Rcm Inc. President since January 2023. Previously, Mr. Sparby was R1 Rcm Inc. Executive Vice President, Operations & Delivery and Chief Operating Officer from January 2021 to June 2022 and R1 Rcm Inc. Executive Vice President, Chief Solutions and Customer Officer from June 2022 to December 2022. Prior to that role, he served as Executive Vice President, Customer Operations as the operational leader of R1 Rcm Inc. revenue cycle customer engagements from January 2017 to December 2020. Mr. Sparby joined R1 in January 2004 as Customer Executive and has since served R1 as Shared Services Operating Executive from January 2008 to December 2010, General Manager, East Region from January 2011 to December 2013, and Senior Vice President, Customer Operations from January 2014 to December 2016. Prior to joining R1, Mr. Sparby spent six years at Stockamp & Associates leading large-scale, end to end revenue cycle re-engineering projects for primarily academic health systems achieving significant income statement and balance sheet improvements.
Lee Rivas

Lee Rivas,自2023年1月起担任R1董事会成员和首席执行官。他曾在2022年6月R1完成对Revint Holdings,LLC(“Cloudmed”)的收购后担任R1总裁,直到2022年12月,在此期间,他领导了Cloudmed成功的交易后整合,在商业卓越、行业专业知识、可扩展技术和智能自动化的基础上建立了一个全面的收入周期平台。里瓦斯先生在技术和医疗保健领域拥有20多年的领导经验。在加入R1之前,他于2020年6月至2022年6月担任Cloudmed首席执行官。从2006年6月至2020年5月,Rivas先生还是全球信息分析解决方案提供商RELX的高级主管。他在RELX的最后一个职位是医疗保健部门的总经理兼总裁,负责Elsevier和LexisNexis风险解决方案部门超过10亿美元的收入。在加入RELX之前,里瓦斯先生是麦肯锡公司的项目经理。他的职业生涯始于美国陆军军官,在美国和国外担任过多个领导职务。里瓦斯毕业于美国西点军校,并拥有哈佛商学院的工商管理硕士学位。


Lee Rivas,has served on the Board and as Chief Executive Officer of R1 since January 2023. He was previously President of R1 from June 2022, when R1 closed the acquisition of Revint Holdings, LLC ("Cloudmed"), until December 2022, during which time he led a successful post-transaction integration of Cloudmed, building a comprehensive revenue cycle platform on a foundation of commercial excellence, industry expertise, scalable technology, and intelligent automation. Mr. Rivas has more than 20 years of leadership experience in technology and healthcare. Prior to joining R1, he was Chief Executive Officer of Cloudmed from June 2020 to June 2022. From June 2006 to May 2020, Mr. Rivas was also a senior leader at RELX, a global provider of information analytics solutions. His last role at RELX was General Manager and President of the healthcare segment, with responsibility over $1 billion in revenue across the Elsevier and LexisNexis Risk Solutions division. Prior to RELX, Mr. Rivas was an engagement manager with McKinsey & Company. He began his career as an officer in the U.S. Army, where he held several leadership positions in the U.S. and abroad. Mr. Rivas is a graduate of the United States Military Academy at West Point and has an M.B.A. from Harvard Business School.
Lee Rivas,自2023年1月起担任R1董事会成员和首席执行官。他曾在2022年6月R1完成对Revint Holdings,LLC(“Cloudmed”)的收购后担任R1总裁,直到2022年12月,在此期间,他领导了Cloudmed成功的交易后整合,在商业卓越、行业专业知识、可扩展技术和智能自动化的基础上建立了一个全面的收入周期平台。里瓦斯先生在技术和医疗保健领域拥有20多年的领导经验。在加入R1之前,他于2020年6月至2022年6月担任Cloudmed首席执行官。从2006年6月至2020年5月,Rivas先生还是全球信息分析解决方案提供商RELX的高级主管。他在RELX的最后一个职位是医疗保健部门的总经理兼总裁,负责Elsevier和LexisNexis风险解决方案部门超过10亿美元的收入。在加入RELX之前,里瓦斯先生是麦肯锡公司的项目经理。他的职业生涯始于美国陆军军官,在美国和国外担任过多个领导职务。里瓦斯毕业于美国西点军校,并拥有哈佛商学院的工商管理硕士学位。
Lee Rivas,has served on the Board and as Chief Executive Officer of R1 since January 2023. He was previously President of R1 from June 2022, when R1 closed the acquisition of Revint Holdings, LLC ("Cloudmed"), until December 2022, during which time he led a successful post-transaction integration of Cloudmed, building a comprehensive revenue cycle platform on a foundation of commercial excellence, industry expertise, scalable technology, and intelligent automation. Mr. Rivas has more than 20 years of leadership experience in technology and healthcare. Prior to joining R1, he was Chief Executive Officer of Cloudmed from June 2020 to June 2022. From June 2006 to May 2020, Mr. Rivas was also a senior leader at RELX, a global provider of information analytics solutions. His last role at RELX was General Manager and President of the healthcare segment, with responsibility over $1 billion in revenue across the Elsevier and LexisNexis Risk Solutions division. Prior to RELX, Mr. Rivas was an engagement manager with McKinsey & Company. He began his career as an officer in the U.S. Army, where he held several leadership positions in the U.S. and abroad. Mr. Rivas is a graduate of the United States Military Academy at West Point and has an M.B.A. from Harvard Business School.
Kyle Hicok

Kyle Hicok,自2023年1月起担任R1 Rcm Inc.执行副总裁兼首席商务官。Hicok先生在收购Cloudmed后加入R1,他在2017年6月至2023年1月期间担任总裁兼总经理。在加入Cloudmed之前,Hicok曾担任过多个职位,负责多州收入周期业务、国家咨询和共享服务业务,包括2014年至2017年在Optum360担任收入周期管理副总裁,2010年至2013年在MedeAnalytics担任多个职务,2008年至2009年在休伦咨询实践部门担任多个职务,2001年至2008年在Stockamp & Associates担任多个职务。希科拥有古斯塔夫斯·阿道夫学院的金融经济学学士学位和佛罗里达大学的工商管理硕士学位。


Kyle Hicok,has served as R1 Rcm Inc. Executive Vice President, Chief Commercial Officer since January 2023. Mr. Hicok joined R1 following the acquisition of Cloudmed, where he served as President and General Manager from June 2017 to January 2023. Prior to Cloudmed, Mr. Hicok served in numerous positions where he was responsible for multi-state revenue cycle operations, national consulting and shared service operations, including as Vice President of Revenue Cycle Management at Optum360 from 2014 to 2017, in various roles at MedeAnalytics from 2010 to 2013, Huron Consulting Group Practice from 2008 to 2009, and Stockamp & Associates from 2001 to 2008. Mr. Hicok has a B.A. in Financial Economics from Gustavus Adolphus College and an M.B.A. from the University of Florida.
Kyle Hicok,自2023年1月起担任R1 Rcm Inc.执行副总裁兼首席商务官。Hicok先生在收购Cloudmed后加入R1,他在2017年6月至2023年1月期间担任总裁兼总经理。在加入Cloudmed之前,Hicok曾担任过多个职位,负责多州收入周期业务、国家咨询和共享服务业务,包括2014年至2017年在Optum360担任收入周期管理副总裁,2010年至2013年在MedeAnalytics担任多个职务,2008年至2009年在休伦咨询实践部门担任多个职务,2001年至2008年在Stockamp & Associates担任多个职务。希科拥有古斯塔夫斯·阿道夫学院的金融经济学学士学位和佛罗里达大学的工商管理硕士学位。
Kyle Hicok,has served as R1 Rcm Inc. Executive Vice President, Chief Commercial Officer since January 2023. Mr. Hicok joined R1 following the acquisition of Cloudmed, where he served as President and General Manager from June 2017 to January 2023. Prior to Cloudmed, Mr. Hicok served in numerous positions where he was responsible for multi-state revenue cycle operations, national consulting and shared service operations, including as Vice President of Revenue Cycle Management at Optum360 from 2014 to 2017, in various roles at MedeAnalytics from 2010 to 2013, Huron Consulting Group Practice from 2008 to 2009, and Stockamp & Associates from 2001 to 2008. Mr. Hicok has a B.A. in Financial Economics from Gustavus Adolphus College and an M.B.A. from the University of Florida.
Jennifer Williams

Jennifer Williams,自2023年1月起担任R1 Rcm公司执行副总裁、首席财务官和财务主管。在收购Cloudmed后,她曾于2022年6月担任执行副总裁兼业务首席财务官,直至2023年1月。在加入公司之前,威廉姆斯女士于2020年7月开始担任Cloudmed的首席财务官。在加入Cloudmed之前,威廉姆斯于2017年10月至2020年7月担任医疗保健技术公司Change Healthcare的高级财务副总裁兼企业职能首席财务官,领导Change Healthcare和McKesson合资企业的财务整合以及随后的首次公开发行。在她职业生涯的早期,威廉姆斯女士是First Advantage的公司财务总监和全球财务负责人,并在LexisNexis Risk Solutions担任过多个领导职位。威廉姆斯女士的职业生涯始于安永。威廉姆斯女士拥有奥本大学会计学学士和硕士学位,是一名注册会计师。


Jennifer Williams,has served as R1 Rcm Inc. Executive Vice President, Chief Financial Officer and Treasurer since January 2023. She previously served as Executive Vice President, Business Chief Financial Officer from June 2022, following the acquisition of Cloudmed, until January 2023. Prior to joining the Company, Ms. Williams served as Chief Financial Officer of Cloudmed beginning in July 2020. Prior to Cloudmed, Ms. Williams served as Senior Vice President, Finance and Chief Financial Officer of Corporate functions for Change Healthcare, a healthcare technology company, from October 2017 to July 2020 and led the financial integration of the Change Healthcare and McKesson joint venture and its subsequent initial public offering. Earlier in her career, Ms. Williams was the corporate controller and global finance leader at First Advantage and held various leadership positions at LexisNexis Risk Solutions. Ms. Williams began her career with Ernst & Young. Ms. Williams holds B.S. and Master of Accountancy degrees from Auburn University and is a Certified Public Accountant.
Jennifer Williams,自2023年1月起担任R1 Rcm公司执行副总裁、首席财务官和财务主管。在收购Cloudmed后,她曾于2022年6月担任执行副总裁兼业务首席财务官,直至2023年1月。在加入公司之前,威廉姆斯女士于2020年7月开始担任Cloudmed的首席财务官。在加入Cloudmed之前,威廉姆斯于2017年10月至2020年7月担任医疗保健技术公司Change Healthcare的高级财务副总裁兼企业职能首席财务官,领导Change Healthcare和McKesson合资企业的财务整合以及随后的首次公开发行。在她职业生涯的早期,威廉姆斯女士是First Advantage的公司财务总监和全球财务负责人,并在LexisNexis Risk Solutions担任过多个领导职位。威廉姆斯女士的职业生涯始于安永。威廉姆斯女士拥有奥本大学会计学学士和硕士学位,是一名注册会计师。
Jennifer Williams,has served as R1 Rcm Inc. Executive Vice President, Chief Financial Officer and Treasurer since January 2023. She previously served as Executive Vice President, Business Chief Financial Officer from June 2022, following the acquisition of Cloudmed, until January 2023. Prior to joining the Company, Ms. Williams served as Chief Financial Officer of Cloudmed beginning in July 2020. Prior to Cloudmed, Ms. Williams served as Senior Vice President, Finance and Chief Financial Officer of Corporate functions for Change Healthcare, a healthcare technology company, from October 2017 to July 2020 and led the financial integration of the Change Healthcare and McKesson joint venture and its subsequent initial public offering. Earlier in her career, Ms. Williams was the corporate controller and global finance leader at First Advantage and held various leadership positions at LexisNexis Risk Solutions. Ms. Williams began her career with Ernst & Young. Ms. Williams holds B.S. and Master of Accountancy degrees from Auburn University and is a Certified Public Accountant.